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Abstract 
Introduction: Progranulin (PGRN) has newly arisen as an important regulatory protein of glucose 
metabolism and insulin sensitivity. Progranulin expression is interrelated with lysosomal function 
strongly linked to autophagy pathway. We aimed to evaluate the correlation between PGRN 
protein and microtubule-associated protein light chain 3B (LC3B) expression level in diabetic 
patients.  
Material and methods: Blood samples of 70 type 2 diabetic Egyptian patients were provided for 
analysis of concentrations of serum progranulin and interleukin 6 (IL-6) using ELISA, and 
quantifying expression of LC3B RNA level using qPCR. A group of 20 healthy volunteers were 
also enrolled.  
Results: Serum levels of PGRN and IL-6 as well as LC3B gene expression levels were markedly 
higher in type 2 diabetic patients.  Additionally, our study revealed a cut-off value of 18.14 ng/mL 
for progranulin serum level and 3.233 for LC3B expression level, with sensitivities of 83.6% and 
75.4% and specificities of 83.8% and 58.3%, respectively. Circulating PGRN levels are positively 
correlated with body mass index (BMI), glucose concentration, and IL-6.  
Conclusion: Our results support the hypothesis that progranulin is introduced as a novel marker 
of chronic inflammatory response in type 2 diabetes that aggravates insulin resistance via activated 
autophagy, indicating the importance of this novel adipokine in the regulation of glucose 
metabolism and as a promising therapeutic target in the treatment of diabetes. 
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Introduction 
Progranulin (PGRN) is a 68–88 kDa cysteine-rich secreted protein, also known as granulin-
epithelin precursor, proepithelin, or PC-cell-derived growth factor [1, 2]. It is encoded by GRN 
(PGRN gene) and expressed in many cell types, including epithelial cells, immune cells, neurons, 
and adipocytes. Progranulin is secreted in an intact form and can be cleaved into granulins by 
proteases [3]. Granulins are small proteins of approximately 6 kDa characterised by a conserved 
motif of 12 cysteines, and they play a role in the extracellular regulation of cell function and growth 
[2].  
Progranulin, as an autocrine growth factor, has recently been found to play a role in a 
variety of physiological and pathological processes, including inflammation, and glucose and lipid 
metabolism [4]. Recent studies found that administration of progranulin caused glucose 
intolerance and insulin insensitivity through the triggering of autophagy in the adipose tissue of 
mice [5], suggesting that progranulin could be a critical adipokine regulating glucose and lipid 
metabolism.  
Progranulin is emerging as an important regulatory adipokine of glucose metabolism and 
insulin sensitivity. Individuals with visceral obesity and type 2 diabetes (T2D) were shown to have 
increased PGRN serum levels [6]. Additionally, circulating PGRN levels are positively correlated 
with body mass index (BMI), fat mass, fasting glucose, insulin levels, and insulin resistance, the 
hallmark of T2D [6, 7]. 
Moreover, it has been found that PGRN plays an important role in inflammation as anti-
inflammatory protein affecting the tumour necrosis factor receptor (TNFR) signalling. 
Additionally, TNFR have been identified as receptors of PGRN. PGRN binds and antagonises both 
TNFR1 and TNFR2, inhibiting TNFα signalling pathway in a dose-dependent manner. The TNFα 
signalling pathway is a major mediator of inflammation, and it is involved in different human 
diseases including diabetes and rheumatoid arthritis [8]. 
Several studies have been performed in order to elucidate the association between PGRN 
and metabolic diseases. Elevated levels of PGRN were found in the white adipose tissue of a well 
characterised mouse model of obesity. The administration of murine recombinant PGRN to wild-
type mice induced an increase of serum insulin level, increased fat mass, insulin resistance, and 
elevated levels of interleukin 6 (IL-6), which is strongly involved in the development of insulin 
resistance [9]. Therefore, PGRN mediates insulin resistance in vivo, inducing IL-6 expression in 
adipose tissue [10]. 
Likewise, it has been found that short-term treatment with recombinant PGRN induces 
insulin resistance both in murine liver and hepatocytes, and this was associated with defective 
autophagy [11]. The relationship between autophagy and PGRN was attributed to the involvement 
of a variety of adipocytokines, including IL-6 and TNFα [12]. Interestingly, PGRN-induced insulin 
resistance and defective autophagy in liver was found to be reverted by the administration of a 
TNFR blocking peptide, thus indicating that PGRN mediates insulin resistance and impaired 
autophagy via TNFR signalling in the liver [11]. 
Furthermore, experimental studies reported that PGRN increases autophagic activity and 
triggers endoplasmic reticulum (ER) stress in cultured human adipocytes, having an impact on 
insulin signalling [9].  
Autophagy is the major mechanism involved in the degradation and recycling of 
intracellular components, and its alterations have been proposed to cause beta cell dysfunction 
[13]. However, autophagy may be enhanced under a variety of atrophic conditions, as shown by 
the expression of several proteins involved in lysosomal degradation, including LC3 [14]. 
Microtubule-associated protein 1A/1B light chain 3B (hereafter referred to as LC3) is a protein 
that in humans is encoded by the MAP1LC3B gene, and it is a member of the highly conserved 
ATG8 protein family. LC3 is a central protein in the autophagy pathway, where it functions in 
autophagy substrate selection and autophagosome biogenesis. LC3 is the most widely used marker 
of autophagosomes [15].  
To the best of our knowledge, we were the first to investigate the correlation between 
PGRN and autophagy with reference to inflammatory response in diabetic patients.  
Material and Methods 
Subjects 
This cross-sectional study was approved by the Ethical Committee of Al-Azhar University and 
was conducted in accordance with the Helsinki Declaration. All subjects signed written, informed 
consent, and this consent procedure was approved by the Ethics Boards of Al-Hussein hospital. 
The analysis was performed on 70 Egyptian patients who were diagnosed with diabetes 
mellitus type 2 and attended the Intensive Care Unit (ICU) of Al-Hussein hospital, Al-Azhar 
University, and 20 healthy normal volunteers age- and sex-matched with the patient group.  
The participant inclusion criteria included being in the age range 35–70 years, having DM and 
hypertension for a minimum of five years, systolic blood pressure > 140 mmHg or diastolic blood 
pressure > 90 mmHg under antihypertensive treatment, and the absence of medication that might 
interfere with urinary albumin excretion. Patients with renal tract pathological conditions, 
cardiovascular disease, non-diabetic kidney diseases, malignancy diagnosis, obstructive uropathy, 
hepatitis, HIV, who had begun dialysis, or had received a renal transplant were excluded from the 
study. 
 
Samples  
A total of 70 blood samples were collected from T2DM patients (41 males and 29 female) in 
addition to 20 samples from healthy persons as control samples (12 males and eight females). Sera 
were collected following a standardised protocol at least 6–8 h after the last meal, from samples in 
sterile falcon tubes, and prepared for RNA isolation and the indicated biochemical analysis then 
stored within 15 min at −80°C.  
 Laboratory and biochemical parameters 
Samples of all participants were labelled with a unique identifier to protect subject 
confidentiality. Blood sugar was measured using the glucose oxidase method, serum glycosylated 
haemoglobin (HbA1c) was tested on an Olympus AU640 (Japan), and cholesterol, high-density 
lipoprotein-cholesterol (HDL-C), as well as low-density lipoprotein–cholesterol (LDL-C) were 
detected on a Hitachi 7180 analyser (Japan) with commercial reagents.  
Body mass index (BMI) was determined as weight (in kilograms) divided by height (in metres) 
squared. Systolic and diastolic blood pressure were measured from the subjects’ right hand using 
a standard mercury manometer, with subjects in a sitting position. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Concentrations of serum PGRN were analysed using a commercially available ELISA kit 
(Wuhan Fine Biotech Co., Ltd, China) and that of serum IL-6 using Quantikine (R&D Systems, 
Inc., USA) according to the manufacturer’s instructions. 
 
Quantitative real‐ time PCR 
Total RNA for LC3B and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was isolated 
using TriZol (Invetrogen) and chloroform then dissolved in RNase free water. The RNA 
concentration and purity were conﬁrmed using an Ultraspec 1000, UV/visible spectrophotometer 
Amersham Pharmacia Biotech, Cambridge, England) and NanoDrop 2000 (Thermo Scientiﬁc, 
USA). 100 ng of total RNA was reverse transcribed into single-stranded complementary DNA by 
using a miScript Reverse Transcription Kit (Qiagen, MD) following the manufacturer’s protocol. 
The synthesised complementary DNA was used for quantitative polymerase chain reaction using 
the qPCR tubes then run on a StepOnePlusTM System (Applied Biosystems, Inc., Foster, CA) in 
the presence of QuantiTect SYBR Green PCR Kit (Qiagen, MD), and the results were 
computerised. The following gene‐ specific primers were used: LC3B-forward-5´- 
ATACBCCTCTCAGGAGACTTT-3´, LC3B-reverse-5´- CCAAATGAGAACTCTGGAACG-
3´, and GAPDH-forward, 5′‐ GTC TCC TCT GAC TTC AAC AGC G‐ 3′ and GAPDH-reverse, 
5′‐ ACC ACC CTG TTG CTG TAG CCA A‐ 3′.  
Target sequences were amplified at 95°C for 15 minutes, followed by 40 cycles at 94°C for 15 
seconds and 55°C for 30 seconds, then for 30 seconds at 70°C. GAPDH was used as an endogenous 
normalisation control. All assays were performed in triplicate. The fold change in messenger RNA 
expression was determined in DM patients compared to controls according to the 2-Δ ΔCt method, 
where ΔCT = CT target gene – CT reference gene and ΔΔCT = ΔCT (sample 2) − ΔCT (sample 
1), and where sample 1 is the control sample and sample 2 is the experimental sample [16]. 
 
Statistical analysis 
Statistical analysis was performed using SPSS version 21.0 (SPSS, Chicago, IL, USA). Data 
are presented as mean ± standard deviation. P < 0.05 was considered statistically significant. 
Differences in the measured expression of MAP1LC3B mRNA between healthy individuals and 
diabetic patient groups were analysed by one-way analysis of variance (ANOVA). Correlations 
were evaluated by Spearman correlation coefficient. The diagnostic accuracy of the progranulin, 
IL-6, and LC3B gene for DM were evaluated by receiver operating characteristic (ROC) analysis.  
 
Results  
The baseline demographic and biochemical characteristics of the study population are 
summarised in Table I. Progranulin and IL-6 showed a significant increase in the diabetic patients 
compared to normal subjects. The expression level of LC3B mRNA was measured, and its level 
was significantly increased in the diabetic patients when compared to the control subjects (Fig. 1). 
The receiver operating characteristic (ROC) curve was designed to distinguish diabetic 
patients from the control group (Fig. 2), and the results revealed that the best cut-off values of 
progranulin, IL-6, and LC3 are 18.14, 1.33, and 3.23, respectively, with certain sensitivities and 
specificities (Tab. II). Combined sensitivities and specificities of PGRN, IL-6, and LC3 are 
represented in Table III.  
Regarding correlations, progranulin levels were positively correlated with BMI, glucose 
concentration, and IL-6. LC3 expression levels were negatively correlated with glucose 
concentration, LDL, CHL, and systolic pressure, and positively with diastolic pressure. Also, 
levels of IL-6 were positively correlated with glucose concentration and systolic pressure (Tab. 
IV). 
 
Discussion 
Progranulin is a protein with growth factor-like properties regulating several biological 
functions. Interestingly, PGRN has been found to be strongly involved in metabolism [17]. 
New markers have been studied in the pathogenesis of diabetes, involving many adipokines 
[18, 19], such as PGRN [7]. There is evidence that PGRN levels are increased in T2DM when 
compared to non-diabetic subjects. PGRN is closely related to glucose metabolism. Furthermore, 
there is a positive correlation between PGRN and plasma glucose A1c [6, 20]. Elevated PGRN 
concentrations are also observed in subjects with impaired glucose tolerance, revealing its role in 
prediabetic states [20].  
In agreement with these findings, the present study showed significantly elevated PGRN 
protein concentration in the diabetic group when compared to the controls; furthermore, HbA1c 
and BMI were significantly increased in the diabetic group. 
Obesity and visceral fat are probably the main risk factors for T2D [9] and are involved in 
its pathophysiology as well as inflammation and insulin resistance [21]. Moreover, a study 
evaluating T2DM patients reported that obese subjects present higher levels of PGRN [13]. Taking 
in consideration the fact that BMI is a simple index of weight-for-height that is commonly used to 
classify overweight and obesity in adults, this study agreed with our finding revealing a significant 
difference of BMI between diabetic and control groups with significant positive correlation with 
PGRN. 
Further studies in the last decade have shown that inflammation is a key process in the 
development of diabetes mellitus [22]. The association of PGRN with T2DM is mainly explained 
by its role in adipose tissue and insulin resistance. Progranulin promotes IL-6 expression, 
impairing insulin signalling [10]. Moreover, it is a chemoattractant protein that recruits monocytes 
into adipose tissue, promoting inflammatory response with increased cytokines levels [6].  
The physiological function of PGRN is complex, with the full-length form of the protein 
having trophic and anti-inflammatory activity, whereas proteolytic cleavage generates granulin 
peptides that promote inflammatory activity [23]. During the inflammatory process, progranulin 
is digested into smaller peptides, called granulins, which are proinflammatory and neutralise the 
anti-inflammatory effect of intact progranulin [24].  
In the current study PGRN concentrations and the inflammatory marker IL-6 are markedly 
elevated in the sera of T2DM. Furthermore, serum PGRN levels had remarkable positive 
correlations with IL-6. Kloeting et al. [25] present evidence that progranulin induces 
proinflammatory IL-6. Therefore, it is speculated that serum PGRN could stimulate the adipocytes 
to release more IL-6. 
Experimental studies reported that PGRN promotes IL-6 expression in adipose cells, and 
its elevation enhances cytokine signaling-3 (SOCS3) expression via activation of JAK-STAT 
signalling. This mechanism can inhibit tyrosine phosphorylation of insulin receptor substrate-1 
(IRS-1), leading to insulin resistance [10].  
Furthermore, Guo et al. [26] explored the mechanism of progranulin action and revealed 
that progranulin treatment activated oxidative stress and endoplasmic reticulum (ER) stress, 
elevated autophagy, and induced insulin insensitivity in adipocytes and adipose tissue of mice.  
Autophagy is a highly conserved pathway. Impairment of autophagy is implicated in the 
pathogenesis of diabetes. Furthermore, autophagy has been closely linked to inflammation in part 
by regulation of adipokine production. Experimental study showed that mice with a conditional 
deletion of autophagy gene (Atg7) in the intestinal epithelium showed enhanced mRNA expression 
of interleukin 1β (IL-1β) [27]. Additional studies in vivo demonstrated that obesity-induced 
endoplasmic reticulum stress causes chronic inflammation in adipose tissue, as shown by up-
regulation of tumour necrosis factor alpha (TNFα), IL-1β, and IL-6 [28]. These observations raised 
the possibility that PGRN might be a promising new link among obesity, autophagy and insulin 
resistance (i.e. diabetes). 
It was revealed that administration of PGRN attenuated insulin signalling and triggered 
autophagy in in vivo and in vitro studies, suggesting a causative role of tumour necrosis factor 
receptor 1 (TNFR1) in PGRN-induced impaired insulin sensitivity, implicating that decreasing 
PGRN level, by influencing its turnover or production, is consequently a promising therapeutic 
approach applied to metabolic disorders [5]. 
Linnemann et al. [29] reported that IL-6 robustly activates signal transducer and activator 
of transcription 3 (STAT3), a transcription factor that is involved in autophagy. The authors also 
reported that IL-6 stimulates LC3 conversion and autophagosome formation in cultured pancreatic 
β cells. In the same study, both mRNA and protein expression of ATG7 (the enzyme responsible 
for the fatty acid conjugation that converts LC3-I to LC3-II) were stimulated by IL-6. IL-6-
mediated regulation of autophagy occurs through multiple complementary mechanisms involving 
both repression of mammalian target of rapamycin complex 1 (mTORC1) and stimulation of 
mammalian target of rapamycin complex 2 (mTORC2). 
Direct stimulation of autophagy is a novel mechanism for IL-6-mediated protection of 
pancreatic β cells from stress-induced apoptosis [29]. This is consistent with previous observations 
that exercise (which stimulates IL-6) activates autophagy in muscle cells and is critical for cellular 
homeostasis [30]. Because the IL-6 receptor and its downstream signalling target are both down-
regulated in human islets in type 2 diabetes [29], IL-6-mediated autophagy stimulation appears to 
be impaired in type 2 diabetes. It is hypothesised that the inability of the diabetic islet to respond 
to increased circulating IL-6 in diabetes may contribute to β-cell dysfunction and death. 
Indeed, the expression level of LC3II is highly correlated with the number of 
autophagosomes [15]. Paula-Gomes et al. [31] reported that LC3 mRNA and, consequently, LC3II 
protein levels were enhanced in the heart tissue of diabetic animals and in fasted cardiomyocytes, 
suggesting that the autophagic flux is increased, which concurred with our findings. In the present 
study, the expression level of LC3B mRNA indicated a significant elevation in the diabetic group 
compared to the normal group.  
On the other hand, insulin treatment of the patient in another study was suggested to be 
responsible for the reduction in the level of LC3B. Also, Su et al. [32] reported that the expressions 
of LC3, ATG5, BECN1, Cathepsin B, and FOXO3A proteins in ovaries from insulin-treated mice 
were significantly reduced compared to those from control mice.  
In addition, in the present study the ROC curve showed that progranulin had higher 
specificity than IL-6 and LC3 but lower sensitivity than IL-6 and higher sensitivity than LC3. The 
combined use of the three parameters increased the sensitivity, reaching 100%. 
Although the potential role of progranulin in activating autophagy and inducing insulin 
resistance has been identified, the intracellular events responsible for progranulin-mediated effects 
in autophagy and diabetes remain not fully understood. 
 
Conclusion 
In conclusion, this body of evidence, combined with our findings, strongly suggests that 
PGRN is a novel marker that plays role in inflammatory response in type 2 diabetic patients via 
activated autophagy. Moreover, this novel adipokine, which is involved in regulation of glucose 
metabolism, could be a promising therapeutic target in the treatment of diabetes. Additionally, 
LC3 has great clinical value as a promising biomarker in diabetic assessment. 
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Figure 1. Differential expression of LC3, protein level of progranulin and IL-6 among different 
groups (n = 90). Values expressed as mean ± SE. *p < 0.05 is significant when compared to 
controls  
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Figure 2. Receiver operating characteristic (ROC) curves of (a) progranulin, (b) interleukin 6 (IL-
6), (c) light chain 3B (LC3) 
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Table I. Clinical characteristics of the participants among the different groups in the study  
 
Groups 
P 
 
F(a) 
 
Diabetic patients Healthy volunteers 
Mean Median ± SD Mean Median ± SD 
Age [years] 
 
54.75 55.00 9.24 54.25 54.50 5.69 0.856 0.33 
BMI [kg/m2] 34.99 35 3.42 28.67 29.00 2.39 0.002* 10.265 
HbA1c (%) 5.80 5.50 0.91 4.87 5.000 0.74 0.001* 11.215 
Glucose [mg/dl] 280.70 262.00 114.35 111.17 111.50 5.32 0.000* 26.072 
SBP [mmHg] 123.60 125.0 9.88 114.17 120.00 9.73 0.003* 9.197 
DBP [mmHg] 80.73 80.00 5.76 79.16 80.00 9.96 0.570 .453 
HDL [mmol/l] 33.72 31.00 8.12 33.67 31.50 8.80 0.983 .000 
LDL [mmol/l] 127.65 118.00 30.15 119.16 110.00 23.25 0.360 0.848 
Cholesterol [mmol/l] 207.24 200.00 33.16 204.16 200.00 29.37 0.766 0.089 
Duration [years] 11.64 12.00 4.66 00 00 00 0.000* 73.961 
BMI — body mass index; HbA1c— glycosylated haemoglobin; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; HDL — high-density lipoprotein; LDL — low-density lipoprotein; SD — standard deviation; aone-way 
ANOVA test; *p < 0.05: significantly different  
 
(c) 
Table II. Area under curve, cut-off value, and performance characteristics of progranulin, 
interleukin 6 (IL-6), and light chain 3B (LC3) to discriminate diabetic patients from the control 
group 
Parameter AUC 
Cut-off 
value 
Sensitivity Specificity 
progranulin 0.878 18.141 83.6% 83.3% 
IL-6 0.918 1.33 88.5% 
75.8% 
 
LC3 0.706 3.233 75.4% 58.3% 
Table III. Combined sensitivity and specificity of progranulin (PGRN), interleukin 6 (IL-6), and 
light chain 3B (LC3) 
Combined parameters Combined Sensitivity Combined Specificity 
PGRN + IL-6 96.7% 83.3% 
PGRN + LC3 96.7% 83.3% 
IL-6+ LC3 100% 75.0% 
PGRN+ IL-6 +LC3 100% 58.3% 
 
Table IV, Correlation between progranulin (PGRN), light chain 3B LC3 (LC3), and interleukin 6 
(IL-6) and clinical parameters among groups of study. 
 
Parameter  PGRN LC3 IL6 
Glucose 
Correlation coefficient (r) .231 –.308 .424 
Sig. (2-tailed) (P) .049* .008* .000* 
HbA1c 
Correlation coefficient (r) .090 –.100 –.098 
Sig. (2-tailed) (P) .451 .400 .411 
BMI 
Correlation coefficient (r) .351 .135 .169 
Sig. (2-tailed) (P) .002* .257 .152 
SBP 
Correlation coefficient (r) .108 –.353 .382 
Sig. (2-tailed) (P) .362 .002* .001* 
DBP 
Correlation Coefficient (r) .075 .257 .055 
Sig. (2-tailed) (P) .527 .028* .643 
HDL 
Correlation Coefficient (r) –.159 –.018 –.013 
Sig. (2-tailed) (P) .179 .878 .916 
LDL 
Correlation Coefficient (r) .165 –.305 .064 
Sig. (2-tailed) (P) .164 .009* .593 
CHL 
Correlation Coefficient (r) .087 –.313 .054 
Sig. (2-tailed) (P) .467 .007* .649 
Duration 
Correlation Coefficient (r) .362 –.042 .394 
Sig. (2-tailed) (P) .002* .725 .001* 
Progranulin 
Correlation Coefficient (r) 1.000 .020 .397 
Sig. (2-tailed) (P) . .865 .000* 
LC3 
Correlation Coefficient (r) .020 1.000 –.122 
Sig. (2-tailed) (P) .865 . .302 
IL-6 
Correlation Coefficient (r) .397 –.122 1.000 
Sig. (2-tailed) (P) .000* .302 . 
BMI — body mass index; HbA1c— glycosylated haemoglobin; SBP — systolic blood pressure; DBP — diastolic blood 
pressure; HDL — high-density lipoprotein; LDL — low-density lipoprotein; Spearman’s correlation p: not significant 
(> 0.05), * p < 0.05: significant 
 
